Omega Therapeutics, Inc. (NASDAQ:OMGA) to Post FY2025 Earnings of ($1.00) Per Share, Chardan Capital Forecasts

Omega Therapeutics, Inc. (NASDAQ:OMGA) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Omega Therapeutics in a note issued to investors on Tuesday, May 7th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($1.00) per share for the year. Chardan Capital currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Omega Therapeutics’ current full-year earnings is ($1.29) per share.

Omega Therapeutics (NASDAQ:OMGA) last posted its earnings results on Thursday, March 28th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Omega Therapeutics had a negative return on equity of 110.41% and a negative net margin of 3,147.92%. The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.93 million.

A number of other research analysts have also recently commented on OMGA. Wedbush reaffirmed an “outperform” rating and set a $12.00 target price on shares of Omega Therapeutics in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Omega Therapeutics in a research note on Tuesday, April 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $9.00 target price (down previously from $10.00) on shares of Omega Therapeutics in a research report on Wednesday, April 3rd.

Omega Therapeutics Trading Down 3.7 %

OMGA stock traded down $0.08 during midday trading on Friday, reaching $2.09. 27,732 shares of the company traded hands, compared to its average volume of 1,607,114. The firm has a market capitalization of $115.26 million, a price-to-earnings ratio of -1.20 and a beta of 1.99. The business has a 50 day moving average of $3.07 and a 200-day moving average of $2.97. Omega Therapeutics has a 52-week low of $1.30 and a 52-week high of $10.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.35 and a current ratio of 3.35.

Institutional Investors Weigh In On Omega Therapeutics

Institutional investors have recently modified their holdings of the business. 683 Capital Management LLC boosted its holdings in Omega Therapeutics by 7.0% in the 3rd quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock worth $1,093,000 after buying an additional 33,242 shares during the last quarter. Murphy Pohlad Asset Management LLC purchased a new position in Omega Therapeutics in the 4th quarter worth approximately $50,000. Finally, Etfidea LLC purchased a new position in Omega Therapeutics in the 4th quarter worth approximately $39,000. 97.47% of the stock is currently owned by institutional investors and hedge funds.

About Omega Therapeutics

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.